PT-141 (Bremelanotide): Evidence, FDA Status, and What's Actually Approved

Most compounds covered on this site share a common problem: they're unapproved, and the marketing pretends otherwise. PT-141 is the opposite case, and it deserves to be treated differently for exactly that reason. PT-141 and bremelanotide are the same molecule — and bremelanotide is FDA-approved, sold under the brand name Vyleesi, for a specific indication in a specific population. That approval is real. What's sold online as "PT-141" research peptide, however, is not the approved product — it's unregulated research-market material claiming to be the same molecule, without the manufacturing oversight, purity verification, or physician supervision that came with the drug that actually went through FDA review. This article separates what the approval covers from what the online market is actually selling.

What Bremelanotide (PT-141) Actually Is and Does

Bremelanotide is a melanocortin receptor agonist — structurally related to the tanning peptide melanotan II, which we cover separately in melanotan II: what the research shows, but developed and studied for an entirely different purpose. Rather than the skin-pigmentation pathway (MC1R), bremelanotide's clinically relevant effect works through melanocortin-4 receptors (MC4R) in the central nervous system, a pathway involved in regulating sexual arousal¹. That's a genuinely distinct mechanism from hormonal therapies — it's not a vasodilator working locally like sildenafil, it's a centrally-acting drug intended to affect desire itself¹.

FDA Approval: Real, Narrow, and Specific

The FDA approved bremelanotide, under the brand name Vyleesi, in June 2019 for a specific indication: treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, when low desire is causing marked distress and isn't explained by another medical or psychiatric condition, a relationship problem, or medication side effects². Read that indication carefully, because it's narrow in three ways the marketing around "PT-141" routinely erases: it's approved for a specific diagnosed condition (not "for anyone wanting more libido"), for premenopausal women only, and only after other causes have been ruled out. It is not approved for men, and it is not approved as a general sexual-enhancement product for anyone²³.

The Trial Data Behind the Approval

The approval rests on the RECONNECT program — two identical Phase 3, randomized, placebo-controlled trials that together enrolled 1,267 women, with 1,202 in the efficacy analysis, over 24 weeks of treatment⁴. The integrated results showed a statistically significant improvement on the Female Sexual Function Index desire domain (a 0.35-point greater increase than placebo, p<.001) and a statistically significant reduction in desire-related distress on the Female Sexual Distress Scale (a −0.33-point greater reduction than placebo, p<.001)⁴. Those are real, positive, statistically significant results from a well-designed trial program — which is exactly why the drug was approved.

But "statistically significant" and "large, clinically obvious effect" are different claims, and this is where bremelanotide gets a more skeptical second look than most approved drugs receive. A 2024 critical reanalysis published in the Journal of Sex Research examined the RECONNECT trial data in more depth, including eight of eleven pre-specified efficacy outcomes that had gone unpublished in the original trial reports, and found effect sizes ranging from nil to small across those measures⁵. The same paper raised a validity concern about the standard measurement tools (FSFI and FSDS-DAO) themselves when applied to women with HSDD specifically, arguing the evidence for their validity in this population is thin⁵. That's a meaningful, published, peer-reviewed critique of an approved drug's evidence base — the kind of scrutiny this site applies to unapproved compounds too, and bremelanotide isn't exempt just because it cleared FDA review.

The Real Side Effects, From the Approved Label

Because bremelanotide is an approved drug, its side-effect profile comes from an actual FDA label rather than scattered case reports — a rare position of clarity in this category. Nausea is the most common adverse reaction, reported in 40% of Vyleesi-treated patients in the Phase 3 trials, with most improvement occurring by the second dose⁶. The label also carries two specific warnings worth taking seriously. First, transient blood pressure increases and heart rate decreases occur after each dose — up to about 6 mmHg systolic and 3 mmHg diastolic — typically resolving within 12 hours, but the label specifically warns against using it more frequently than directed because more frequent dosing produces more pronounced increases⁶. Second, focal skin hyperpigmentation — darkening of the face, gums, or breasts — was reported in about 1% of patients using up to 8 doses monthly, with higher risk in patients with darker skin and with more frequent dosing, and the label notes that resolution wasn't confirmed in every affected patient⁶. The approved dosing ceiling reflects those risks directly: no more than one dose in 24 hours, and no more than 8 doses per month⁶.

What "PT-141" Sold Online Is Actually Buying You

This is the gap that matters most for anyone searching "PT-141" rather than "Vyleesi." The approved product is manufactured under FDA-regulated conditions, prescribed after a clinical evaluation, and dosed within limits specifically calibrated against the blood-pressure and hyperpigmentation risks above. A vial labeled "PT-141" bought from a research-chemical website carries none of that — no verification that it contains the labeled amount of bremelanotide, no clinical screening for the cardiovascular considerations the label warns about, and no guidance on the dosing ceiling that exists specifically to limit hyperpigmentation and blood-pressure risk. Using an unverified vial at an unsupervised, uncapped frequency reproduces exactly the two risk factors — excess frequency and unknown dose — that the approved label was written to prevent. We cover the broader unregulated-supply problem in peptide vendor red flags and scams and how to verify a peptide's COA and third-party testing; for men specifically, note that bremelanotide has no FDA approval for male sexual dysfunction at all, so any male-marketed "PT-141" use is entirely off-label and unstudied at the population level, regardless of vial purity.

Bottom Line

PT-141 is the unusual case on this site where the underlying molecule, bremelanotide, genuinely is FDA-approved — as Vyleesi, for premenopausal women with a specific diagnosed desire disorder, based on two positive Phase 3 trials. That's real regulatory and clinical evidence most compounds covered here simply don't have. But the approval is narrower than the marketing implies (not for men, not for general enhancement), the effect size behind it has drawn a serious published critique questioning how much of the RECONNECT program's benefit is clinically meaningful versus merely statistically significant, and the side-effect profile — 40% nausea, transient blood pressure changes, and a hyperpigmentation risk with unclear reversibility — is real enough that the FDA capped dosing frequency specifically to manage it. None of that transfers automatically to a research-chemical vial bought online with no verification of contents, no clinical oversight, and no dosing ceiling enforced. The molecule earned its approval; a website selling "PT-141" without a prescription did not earn the same trust.